Haisco Pharmaceutical Group (002653.SZ) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

002653.SZ · Stock Price

CNY 57.66+15.21 (+35.83%)

Market Cap: $9.0B

Historical price data

Overview

Haisco Pharmaceutical Group's mission is to develop and deliver innovative, high-quality medicines to address unmet medical needs in China and globally. The company has achieved significant scale, becoming one of China's top pharmaceutical firms by market value, through a successful 'generic-to-innovative' transition strategy. Its core strategy is built on vertical integration, using stable cash flows from its generics and established drug portfolio to fund R&D in high-growth therapeutic areas, while expanding its commercial reach across China's vast healthcare market.

OncologyCardiovascularRespiratoryMetabolicCentral Nervous System

Technology Platform

An integrated pharmaceutical engine combining targeted drug discovery, clinical development expertise in the Chinese regulatory landscape, and vertically advanced manufacturing capabilities for APIs and complex finished dosage forms.

Pipeline

128

128 drugs in pipeline23 in Phase 3

Drug	Indication	Stage
Crisugabalin + Placebo	Parkinson's Disease With Nociceptive Pain	Approved
Polyene phosphatidylcholine injection 930 mg QD + Magnesium ...	Acute Drug Induced Liver Injury	Approved
Cyclopofol + Propofol	Postoperative Delirium	Approved
Ciprofol + Propofol	Anesthesia, General	Approved
Cipepofol	Anesthesia	Approved

Funding History

1

IPOUndisclosedUndisclosedMar 15, 2012

Opportunities

Haisco is poised to capitalize on China's aging population and rising chronic disease burden, particularly in oncology and metabolic diseases.

Its late-stage innovative pipeline offers near-term catalysts, while its integrated model provides cost advantages and a powerful commercial engine for launching new products.

Government policy favoring domestic innovation further supports its growth trajectory.

Risk Factors

Major risks include clinical trial failures in key late-stage programs, intense pricing pressure from China's national drug procurement policies, and fierce competition from both global pharma and a crowded field of domestic biotech innovators.

Successful growth depends on balancing cash flow from legacy generics with investment in higher-risk R&D.

Competitive Landscape

Haisco competes with global pharmaceutical multinationals on local agility and cost, and with leading Chinese innovators like Hengrui and BeiGene on R&D prowess and commercial execution. Its primary competitive advantages are its fully integrated business model, massive domestic commercial footprint, and strong balance sheet, allowing for sustained investment.

More companies in Small Molecule Drugs →More companies in China →